Lessons learned from recent clinical trials in hypertensive diabetics: What's good for the kidney is good for the heart and brain

American Journal of Hypertension

Volumn 17, Issue 11 SUPPL., 2004, Pages S7-S10

  Toto, Robert D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; hypertension; renin angiotensin aldosterone system

Indexed keywords

ALBUMIN; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; IRBESARTAN; LOSARTAN; RAMIPRIL;

BRAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HEART; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; KIDNEY DISEASE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 7944223782     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.08.003     Document Type: Article

References (15)

1. J. Stamler, O. Vaccaro, J.D. Neaton, D. Wentworth Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
2. US Renal Data System: USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2003 National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases Bethesda, MD
3. M.A. Gall, K. Borch-Johnsen, P. Hougaard, F.S. Nielsen, H.H. Parving Albuminuria and poor glycemic control predict mortality in NIDDM Diabetes 44 1995 1303 1309
4. R.G. Nelson, P.H. Bennett, G.J. Beck, M. Tan, W.C. Knowler, W.E. Mitch, G.H. Hirschman, B.D. Myers Diabetic Renal Disease Study Group Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus N Engl J Med 335 1996 1636 1642
5. G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, R. Toto, K. Tuttle, J. Douglas, W. Hsueh, J. Sowers National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving renal function in adults with hypertension and diabetes a consensus approach Am J Kidney Dis 36 2000 646 661
6. S. Yusuf, P. Sleight, J. Pogue, R. Davies, G. Dagenais Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
7. L.H. Lindholm, H. Ibsen, B. Dahlöf, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristiansson, O. Lederballe-Pedersen, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J.M. Edelman, S. Snapinn LIFE Study Group Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 1004 1010
8. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
9. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
10. H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
11. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, I. Raz Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
12. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
13. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
14. L.H. Lindholm, H. Ibsen, K. Borch-Johnsen, M.H. Olsen, K. Wachtell, B. Dahlof, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristianson, O. Lederballe-Pedersen, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J.M. Edelman, S. Snapinn LIFE Study Group Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study J Hypertens 20 2002 1879 1886
15. American Diabetes Association Hypertension management in adults with diabetes Diabetes Care 27 Suppl 1 2004 S65 S67